Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
This study has been terminated.
(trial stopped on Sept 24, 2007)
Information provided by:
First received: September 9, 2005
Last updated: August 8, 2008
Last verified: August 2008
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
Proliferative Diabetic Retinopathy
Drug: Octreotide, 30 mg i.m. LAR formulation
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation
Primary Outcome Measures:
- regression of neovascularization.
Secondary Outcome Measures:
- Determine tolerability and safety
| Estimated Enrollment:
| Study Start Date:
| Primary Completion Date:
||May 2006 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years to 70 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with type-I or type-II-diabetes mellitus.
- Males or females aged 18 - 70 years.
- Proliferative diabetic retinopathy (PDR) in at least one eye that has an ETDRS visual acuity score > 35 letters (20/200 or better), and that has no other condition that might interfere with assessment of retinopathy progression (see exclusion criterion #1).
- Media clarity, pupillary dilation and patient cooperation sufficient to allow stereoscopic 30°, or equivalent, fundus photographs of adequate quality in at least one eye that meets criterion #3 above.
- Starting of photocoagulation of at least one eye to treat PDR in between approximately 2 weeks prior to start of study.
- HbA1c < 13.0% at study entry. In addition, patients must be capable of testing their blood glucose levels at home and adjusting their insulin dosage to maintain blood glucose control.
- Systolic blood pressure < 180 mm Hg and diastolic blood pressure < 105 mm Hg at study entry.
Females of childbearing potential must:
- Have a negative pregnancy test prior to study entry.
- Be practicing acceptable birth control measures inclusive of intrauterine devices or mechanical methods (i.e., oral contraceptives, vaginal diaphragm, vaginal sponge or condom with spermicide).
- Ability to read, understand and write German language
- Patients must give written informed consent to participate in this study.
- Pretreatment as panretinal laser treatment other than photocoagulation which started approximately 2 weeks prior to start of study (see inclusion criteria # 5).
- Patients in whom the only otherwise eligible eye has, in the opinion of the investigator or of the central fundus photograph reading center, a condition that might interfere with assessment of retinopathy progression, including optic atrophy, extensive healed chorioretinitis, retinopathy that appears to have regressed spontaneously (with or without traction retinal detachment), retinal vascular occlusion, retinal degeneration, or other abnormality.
- Patients with a history of symptomatic gallstones who have not had a cholecystectomy (patients with asymptomatic cholelithiasis may be entered).
- Patients with brittle diabetes, type-I diabetes who have frequent decompensations in their glycemic control, with recurrent ketoacidosis or hypoglycemia that significantly interferes with their lifestyle.
- Patients with a history of severe hypoglycemia unawareness.
- Patients with a significant medical condition, other than diabetes mellitus, which may interfere with the evaluation of safety or efficacy of the study compound (e.g., unstable angina pectoris, myocardial infarction within 3 months prior to study entry, severe renal failure, patients on renal dialysis, patients who have received a renal transplant).
- Patients who have received any investigational drug within 4 weeks prior to study entry.
- Patients who have received prior treatment with Sandostatin or any other somatostatin analogue.
- History of non-compliance to medical regimens or who are considered potentially unreliable Other protocol-defined inclusion/exclusion criteria may apply.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00170742
|Basel, Switzerland |
||Novartis Customer Information
No publications provided
History of Changes
|Other Study ID Numbers:
||CSMS 995 H DE 07
|Study First Received:
||September 9, 2005
||August 8, 2008
||Germany: Federal Institute for Drugs and Medical Devices
Keywords provided by Novartis:
proliferative diabetic retinopathy, lasercoagulation
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 22, 2013
Endocrine System Diseases
Antineoplastic Agents, Hormonal